06
FEB
2017

NW Bio Announces Lifting of Clinical Hold on DCVax®-L Phase III Trial By FDA; Progression-Free Survival Events Reached; Overall Survival Events Not Yet Reached

Posted By :
Comments : Off
Process Now Moving Forward Toward Data Lock   BETHESDA, Md., February 6, 2017 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio” or the “Company”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today provided a further update about the Company’s Phase III trial of DCVax®-L for Glioblastoma multiforme (“GBM”) brain cancer (the “Trial”).  The Company announced that the partial...
Read More
18
JAN
2017

NW Bio Presenting At Phacilitate Immunotherapy World Conference

Posted By :
Comments : Off
BETHESDA, MD, January 18, 2017 – Northwest Biotherapeutics, Inc. (OTCQB: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers, announced today that Dr. Marnix Bosch, Chief Technical Officer of NW Bio, will present at the Phacilitate Immunotherapy World Conference on Thursday, January 19, 2017, at the Hyatt Regency Hotel in Miami, Florida. Dr....
Read More
19
DEC
2016

NW Bio Announces Initiation Of Trading On The OTCQB Marketplace Starting On Monday Morning, December 19, 2016

Posted By :
Comments : Off
BETHESDA, Md., December 19, 2016 – Northwest Biotherapeutics (Nasdaq: NWBO) (“NW Bio” or the “Company”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that its common stock will begin trading on the OTC Market Group’s OTCQB marketplace effective at the open of the market on Monday, December 19, 2016.  The Trading symbol will remain NWBO. As of this morning, t...
Read More
08
DEC
2016

NW Bio Provides Update About Phase 3 Trial Of DCVax®-L for Newly Diagnosed Glioblastoma Multiforme Brain Cancer

Posted By :
Comments : Off
Trial Enrolled 331 Patients; Data “Events” Accumulating Towards Trial Endpoints BETHESDA, Md., December 8, 2016 – Northwest Biotherapeutics (Nasdaq: NWBO) (“NW Bio” or the “Company”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today provided an update about the Company’s Phase 3 trial of DCVax®-L for Glioblastoma multiforme (GBM) brain cancer (the “Trial”).  The Company announced...
Read More
07
DEC
2016

NW Bio Announces Decision to Voluntarily Withdraw from Nasdaq Listing and Begin Trading on OTC Market

Posted By :
Comments : Off
BETHESDA, Md., December 7, 2016 – Northwest Biotherapeutics (Nasdaq: NWBO) (“NW Bio” or the “Company”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the Nasdaq Staff has not accepted the Company’s plan of remediation for certain violations of Listing Rules previously reported, and the Company has notified Nasdaq of its intention to voluntarily withdraw t...
Read More